MERSYNDOL WITH CODEINE 8 MG
CODEINE PHOSPHATE : 8 MG DOXYLAMINE SUCCINATE : 5 MG ACETAMINOPHEN : 325 MG · DIN 02047667 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is MERSYNDOL WITH CODEINE?
MERSYNDOL WITH CODEINE 8 MG contains CODEINE PHOSPHATE : 8 MG DOXYLAMINE SUCCINATE : 5 MG ACETAMINOPHEN : 325 MG. It is listed in the Health Canada Drug Product Database under DIN 02047667, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Nov-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MERSYNDOL WITH CODEINE used for?
Relief of headaches, cold symptoms, muscular aches and pains in patients older than 18 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02047667 |
|---|---|
| Brand name | MERSYNDOL WITH CODEINE |
| Generic / active ingredient | CODEINE PHOSPHATE : 8 MG DOXYLAMINE SUCCINATE : 5 MG ACETAMINOPHEN : 325 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 8 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02BE51 ACETAMINOPHEN, COMB EXCL PSYCHOLEPTICS |
| AHFS class | 04:04.04 ; 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Nov-2007 |
| Original market date | 1982-12-31 00:00:00 |
How is it administered?
Adults (18+): 1-2 tablets every 4 to 6 hours as required. Maximum 12 tablets in a 24-hour period.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in provided text (refer to section 11).
How is it supplied?
HDPE bottles of 100 tablets.
Contraindications
Hypersensitivity to ingredients; MAOI use within 14 days; respiratory depression/insufficiency; last trimester of pregnancy/labor; breastfeeding; CYP2D6 ultra-rapid metabolisers; children <12 years.
Warnings and precautions
May cause drowsiness; avoid driving/machinery. Risk of opioid toxicity in ultra-rapid metabolisers. Potential for dependence/abuse. Risk of severe skin reactions (SJS/TEN) and hepatotoxicity.
What can be used instead?
Other Canadian products sharing ATC code N02BE51 ACETAMINOPHEN, COMB EXCL PSYCHOLEPTICS. 133 of 747 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACETAMINOPHEN WITH ANTIHISTAMINE NIGHTTIME | 25 MG | TABLET | LABORATOIRES TRIANON INC. | MARKETED | DIN 02238183 |
| ADVIL PLUS ACETAMINOPHEN | 125 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 02519267 |
| BENADRYL ALLERGY, SINUS & PAIN TOTAL | 25 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02250993 |
| BENYLIN EXTRA STRENGTH ALL-IN-ONE COLD, FLU & COUGH | 100 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02218186 |
| BENYLIN EXTRA STRENGTH ALL-IN-ONE COLD, FLU & COUGH NIGHT | 30 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02256576 |
| BENYLIN EXTRA STRENGTH ALL-IN-ONE COUGH, COLD & FLU | 500 MG / 15 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02245710 |
| BENYLIN EXTRA STRENGTH ALL-IN-ONE COUGH, COLD & FLU NIGHT | 2 MG / 15 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02252376 |
| BENYLIN EXTRA STRENGTH ALL-IN-ONE COUGH, COLD & FLU WITH WARMING SENSATION | 30 MG / 15 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02321432 |
| BENYLIN EXTRA STRENGTH COLD & SINUS DAY | 5 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02273462 |
| BENYLIN EXTRA STRENGTH COLD & SINUS NIGHT | 2 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02306409 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.